Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.15.1 (
ACE
)
18,300
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The renin-angiotensin system plays an important role in renal growth and development. Exposure of the neonate to
angiotensin converting enzyme
(
ACE
) inhibitors increases mortality and results in growth retardation and abnormal renal development. It has been demonstrated that
ACE
inhibition in the developing kidney reduces the renal expression of growth factors, which may account for renal growth impairment. This study was designed to investigate the relationship between renal growth impairment and the expression of transforming growth factor-beta1 (TGF-beta1), TGF-beta receptor I [TbetaRI, activin-like kinase (ALK)-1 and
ALK-5
], and TGF-beta receptor II (TbetaRII). Newborn rat pups were treated with enalapril (30 mg/kg per day) or vehicle for 7 days, and kidneys were removed for Western blotting of TGF-beta1, ALK-1,
ALK-5
, and TbetaRII, and for RT-PCR of
ALK-5
and TbetaRII. TGF-beta1, ALK-1,
ALK-5
, and TbetaRII were also detected by immunohistochemistry. Enalapril treatment resulted in an increased mortality (30.4%) by day 7, and reduced body weight and kidney weight ( P<0.05 versus vehicle). Enalapril decreased renal TGF-beta1, ALK-1, and
ALK-5
protein expression ( P<0.05). Also, enalapril decreased
ALK-5
mRNA expression ( P<0.05). TbetaRII expression was not changed by enalapril treatment. These results indicate that
ACE
inhibition in the developing kidney decreases TGF-beta1, ALK-1, and
ALK-5
expression, which may account for renal growth impairment. TbetaRII may not be modulated by
ACE
inhibition in the developing kidney.
...
PMID:ACE inhibition modulates transforming growth factor-beta receptors in the young rat. 1288 79
